盆炎丸治疗多重耐药解脲支原体感染的临床观察

目的观察盆炎丸治疗多重耐药支原体感染的临床疗效。方法将60例多重耐药支原体感染患者随机分为2组,治疗组30例口服盆炎丸,对照组30例口服强力霉素,14 d为1个疗程,两组均连续治疗3个疗程,观察2组治疗前后临床证候积分,判断其临床疗效。结果治疗组综合疗效总有效率为83.3%,对照组总有效率为63.3%,两组比较,差异无统计学意义(P>0.05)。在中医证候改善方面,治疗组明显优于对照组(P<0.01)。结论在综合疗效方面,盆炎丸治疗多重耐药支原体感染疗效与强力霉素相当,但在中医证候改善方面,盆炎丸有明显优势,值得临床推广。     

针刺辨证治疗功能性消化不良的临床观察

目的观察针刺辨证治疗功能性消化不良(FD)的临床疗效。方法应用随机数字表将88例研究对象分为治疗组44例、对照组44例。治疗组根据患者辨证分型的不同,分别施以相应的针刺方案治疗;对照组则不辨证统一采用单纯针刺方案治疗。观察患者治疗前后证候积分及疗效指数、SF-36评分、尼群消化不良指数(NDI)以及血浆胃动素(MTL)的变化。结果治疗组脱失1例,总有效率93.02%;对照组脱失2例,总有效率76.19%;两组差异有统计学意义(P<0.05)。治疗完成和1月后随访时,两组相对治疗前症状指数(NDSI)显著降低,生活质量指数(NDLQI)、健康相关生活质量评分(SF-36)均显著增加(P<0.05);与同期比较治疗组NDSI明显低于对照组,NDLQI、SF-36明显高于对照组(P<0.05)。结论对FD患者进行辨证针刺和不辨证针刺都是有效的治疗手段,但是辨证针刺组的总有效率及近远期的疗效均明显优于对照组。     

祛风化痰针刺法改善假性球麻痹吞咽功能障碍的多中心临床观察

目的系统观察祛风化痰针刺法改善假性球麻痹患者吞咽功能障碍的作用。方法将240例确诊为风痰型假性球麻痹的患者随机分为治疗组和对照组,每组各120例,分别给予祛风化痰针刺法和模拟针刺法治疗,取穴风池(双)、完骨(双)、廉泉、丰隆(双)。每天上、下午各针刺1次,连续6 d为1疗程,疗程间休息1 d,治疗4个疗程。采用洼田饮水试验方法于治疗前、治疗2、4个疗程后进行吞咽功能级别评定,4个疗程后进行疗效评定和比较。结果第2个疗程结束后两组患者的吞咽功能评级与治疗前比较有较显著的提高,差异有统计学意义(P<0.01),治疗组优于对照组(P<0.05);与治疗前比较,第4疗程结束后吞咽功能评级进一步显著提高,差异有统计学意义(P<0.01),治疗组较对照组更优,差异有统计学意义(P<0.01);治疗组的治愈率、显效率和总有效率均显著高于对照组,差异有统计学意义(P<0.01)。结论祛风化痰针刺法改善假性球麻痹患者吞咽功能有肯定、持续且显著的作用,有较大的临床应用价值。     

禽流感防制进展

禽流感（Avian influenza,AI）是由A型流感病毒所引起的禽类的一种传染病。能引起禽类呼吸系统到严重全身败血症等多种症状的烈性传染病。禽类感染后病死率很高,但对野生禽类多为不显性感染。自从1997年香港发生禽流感病毒H5N1亚型首次突破种属屏障感染人类并引起死亡以来,世界各国纷纷报道各种人禽流感病例的发生,人禽流感的关注程度也达到了前所未有的高度。近几年全球共有三大洲的19个国家和地区发生禽流感疫情。一些地区的疫情呈现蔓延的趋势,并且出现了人感染禽流感病毒的病例。禽流感不仅对养殖业造成重大损失,更对人类健康造成严重威胁。本文全面地介绍了禽流感的病原、流行病学、临床症状、病理变化、诊断和防制。     

伪狂犬病病毒野毒荧光定量PCR检测方法的建立

根据伪狂犬病病毒gE基因的序列,设计和合成了一对特异的可用于检测伪狂犬病病毒野毒的PCR引物和一条Taqman荧光探针,采用Li ght Cycl e 480荧光定量PCR仪,建立了一种可实时定量检测伪狂犬病病毒野毒的荧光定量PCR技术。该方法的线性范围为1.0×102～1.0×1010拷贝,灵敏度可达4拷贝。检测速度快,仪器的运行时间仅为1 h。对13株猪伪狂犬病病毒野毒进行了检测,结果均为阳性;与伪狂犬病gE基因缺失疫苗、猪细小病毒和鸭瘟病毒无非特异性反应。与病毒分离培养比较,该方法具有快速、灵敏、特异、定量、重复性好等优点,可望用于临床上伪狂犬病病毒野毒与疫苗毒的区分,伪狂犬病病毒野毒的检测和病毒分布的研究等。     

Assessment of quality of life in equine patients

Reasons for performing study: Assessing patients' quality of life (QOL) is a core part of clinical decision making. Various methodologies for assessing patients' QOL have been developed in human medicine and small animal veterinary disciplines. In contrast, the lack of aids for QOL assessment in equine veterinary practice leaves practitioners reliant on subjective assessments of QOL, which may be prone to avoidable errors. Objectives: This paper suggests pragmatic ways in which QOL may be enhanced, while remaining appropriate for the time, financial and owner‐based constraints within equine practice. Methods: Through interdisciplinary research, this paper identifies, adapts and applies insights from several areas of research and practical experience in order to develop an overarching approach to making QOL‐based decisions in clinical cases. Results: The paper identifies 6 steps involved in QOL‐based decision making and provides examples of how these steps may be practically applied. These include deciding what each clinician feels is important; deciding how to evaluate it, including taking owners' views into consideration; making decisions about each case and achieving the desired clinical outcomes. Conclusions: Practitioners can draw their own conclusions on how they may improve QOL assessment in practice and may usefully share these with colleagues. Reporting cases and sharing practical examples of QOL tools used on the ground are vital to the development of this field and appropriate methodologies. Potential relevance: Improvements in QOL assessment are relevant to all areas of equine veterinary practice, and several areas of research. Further research may develop QOL assessment in practice, but more important are the personal improvements that each practitioner may achieve. See also correspondence by Grove     

蚯蚓纤溶酶的分离纯化及临床作用研究进展

蚯蚓纤溶酶是从蚯蚓中分离的一种丝氨酸蛋白水解酶,有抗凝溶血栓、抗癌抗肿瘤、抗炎、神经修复等作用,在临床上是预防和治疗血栓疾病的有效药物。本文对蚯蚓纤溶酶的分离纯化与药理作用加以概述,为临床蚯蚓溶栓药物的研究提供依据。     

Phase II clinical evaluation of lomustine chemotherapy for feline vaccine‐associated sarcoma

Treatment of feline vaccine‐associated sarcoma (VAS) is challenging, in part due to the high likelihood of tumour recurrence despite aggressive local therapy. Lomustine is potentially an attractive agent to add to the current treatment armamentarium. In this de‐escalating phase I/II prospective trial, 28 cats with measurable VAS were treated at target dosages of 38–60 mg m^?2 every 3 weeks until disease progression. The overall response rate was 25%, with a median progression‐free survival and median duration of response of 60.5 and 82.5 days, respectively. Haematologic toxicity, specifically cumulative neutropenia, was significant, and dose reductions and treatment delays were common. Although these data support further investigation of lomustine for the treatment of VAS, safe, multidosing protocols must first be determined.